News and Trends 4 Apr 2015
News and Trends
- Latest Posts
News and Trends 3 Apr 2015
Back to Middle Age to re-discover some medicinal treatments
The long medieval period extends in the West over nearly a millennium and gradually enriched its knowledge in the medical field. Admired by the Greeks, Egyptian medicine made reference in Western medicine for millennia. Medical papyri mention over seven hundred healing substances, plant, animal, mineral, composing over a thousand remedies often associated with incantations to […]
News and Trends 3 Apr 2015
The Strategic Focus of Roche-Genentech on Personal Genetic data
Personal Genetic data plays more and more a critical role in drug development. Major Pharma company Roche and its Biotech subsidiary Genentech are iconic in this trend. They have always been the first ones to catch up the wave and get profit from it. Today, Genentech believes and focus on genome sequencing to continue bringing breakthrough […]
News and Trends 2 Apr 2015
Anergis completed Phase II for AllerT, a novel treatment for pollen allergies
Anergis announced treatment completion of its Phase II clinical trial of AllerT, a novel long-peptide immunotherapeutic to treat birch pollen allergies. Anergis’ approach uses synthetic, pharmaceutical-grade Contiguous Overlapping Peptide (“COP”), peptides of 40-80 amino-acids which are safer (no risk of immediate allergic reaction) and can elicit a faster immune response than the allergenic proteins they […]
News and Trends 2 Apr 2015
Interview with CELLPROTHERA, the regenerative medicine pioneer
CellProthera is a medical biotech company founded in 2008 in Mulhouse, France. The young innovative company focuses on the use of blood peripheral stem cells. CellProthera is the origin of a revolutionary therapy allowing the regeneration of myocardial tissue following acute myocardial infarct (AMI) by injection of a cell graft containing autologous adult stem cells […]
News and Trends 1 Apr 2015
Cardio3 will launch an IPO in the United States
Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined. A draft registration statement relating to […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 31 Mar 2015
Merck Serono and Intrexon, to develop CAR-T Therapy
Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, […]
News and Trends 30 Mar 2015
#BioFigures: €406 Million Antibody-drug conjugate Deal struck by ImmunoGen andTakeda
WHO? ImmunoGen is a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology. The Company’s uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The first product with ImmunoGen’s ADC technology is Roche‘s Kadcyla. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds […]
News and Trends 28 Mar 2015
Strategic Partnership Between Green Cross and Nanolek
The South Korean biopharmaceutical company Green Cross and the Russian pharmaceutical company Nanolek signed a strategic partnership agreement for the commercialisation of Green Cross’ biologics in the Russian market. Green Cross provides healthcare solutions that address the evolving needs of human health. The company is specialised in the development and manufacturing of plasma-derivatives, vaccines and recombinant […]
News and Trends 27 Mar 2015
OSE Pharma raised €21.1 Million
OSE Pharma’s Initial Public Offering couldn’t have been more successful as it just raised €21.1M. Noticing the strong demand for shares, the board of OSE Pharma has increased the price of the capital to €10.80 per share, corresponding to the top of the indicative price range of the offer. On this basis, the market capitalization […]
News and Trends 26 Mar 2015
With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever
Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources […]
News and Trends 26 Mar 2015
The Metamorphosis of Biopharmaceutical Innovation #BIO-Europe2015
Innovation can occur in many different ways, and biopharmaceutical innovation is no exception. The pipelines of big Pharmas have fewer candidates, R&D costs are skyrocketing, internal research programs tend to shrink and open innovation is raising. This metamorphosis is happening right now and the plenary session of Bio-Europe Spring 2015 focused on this subject. A great opportunity […]
ADVERTISEMENT
